Over the past decade, clinical trial quality has evolved from an after-the-fact, reactive activity to one focused on the important work of evidence generation from well-designed trials. This article explores the role the Clinical Trials Transformation Initiative has played in advancing quality as a core element of clinical trial design, through project work that initially focused on monitoring but evolved into a holistic, prospective, and comprehensive quality by design approach to clinical trial design and conduct.
Over the past decade, clinical trial quality has evolved from an after-the-fact action, ancillary to the science of clinical trials, to a core element of clinical trial design ( Figure 1 ). This article explores the key role the Clinical Trials Transformation Initiative (CTTI) has played in this transformation, focusing primarily on quality in medical product development for regulatory approval.
Clinical trial conduct and oversight in the early 2000s
At the close of the 20th century, the clinical trials ecosystem faced significant operational challenges. Trials were exceedingly complex and required an array of third parties to support their design and execution. Medical products were developed for a global marketplace, necessitating multi-regional clinical trials and widely dispersed clinical investigator sites. Additionally, the expense of completing trials, whether in an academic or industry setting, 1 began to threaten ongoing evidence generation.
Many clinical development organizations responded to these challenges by trying to root out inefficiencies and waste. One common industry approach was applying Six Sigma methodologies to streamline the process of conducting trials. Performance metrics emphasized speed, cycle time, and budget. These efforts to simplify clinical trial processes and the resultant metrics did not always give appropriate weight to trial-related activities underpinning the credibility of trial conclusions and overall quality. In fact, clinical trial quality was often confined to two verification activities outlined in the 1996 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (ICH E6) guideline: on-site monitoring (quality control) and audits (quality assurance). 2 As a result, quality was reactive. Clinical quality professionals focused on uncovering and correcting any issues that might be detected during a regulatory inspection, regardless of overall importance to data integrity or participant safety. Auditors and monitors were often viewed as police rather than partners: they checked that data points were accurate, ensured trial documentation was filed in an orderly fashion, issued findings on any noted discrepancies, and then moved on to the next monitoring visit or audit. In this environment, quality professionals struggled to be effective in creating sustainable quality improvements.
Moreover, the overemphasis on trial efficiency led many organizations to further outsource clinical trial activities to service providers who could provide flexible resources for study monitoring and other operational activities. Executing a clinical trial became a business with small margins. With quality in clinical trials firmly established as an absence of error, sponsors felt compelled to add even more resources and quality checks to monitor the work completed by these third parties. Service providers were penalized for what errors were detected, impacting their businesses and creating a barrier to effective partnerships.
Ultimately, this stringent but superficial approach to quality left sponsors awash in a sea of issues and corrective actions that competed with the important work of evidence generation from well-designed trials. Many organizations struggled to identify true quality or compliance signals amidst the noise and diluted resources that could be better spent addressing important errors.
The turning point
The situation came to a head in 2009 and 2010 (Figure 1 ), when a series of high-profile U.S. Food and Drug Administration (FDA) warning and complete response letters highlighted significant and systemic deficits in trial conduct and oversight that had gone largely undetected by sponsors and contract research organizations in spite of traditional monitoring and auditing. 3, 4 Around the same time, the FDA and the European Medicines Agency (EMA) initiated a good clinical practice (GCP) collaboration, including information sharing on inspectional approaches and outcomes. 5 Both regulators recognized a need for change in how industry approached clinical trial quality and acknowledged that resources should be focused on addressing important and likely errors with the potential to undermine data integrity or participant safety. An important aspect of this challenge was shifting the culture of quality to one that valued proactive, collaborative approaches and considered quality an inherent part of trial design, conduct, and reporting, rather than a separate oversight function.
CTTI takes a leadership role in redefining trial quality CTTI, with its diverse membership, was well-positioned to help modernize quality practices and drive cultural change. Its structure enabled and encouraged stakeholders across the trial ecosystem to collaborate, evaluate, and solve pressing issues in the clinical trial enterprise. Members' misgivings about monitoring prompted CTTI to strategically target clinical trial monitoring for its first foray into quality in 2009. Regulators shared concerns that monitoring was not functioning as an effective quality control. In parallel, industry members had made significant investments in assuring quality monitoring but realized a decreasing return-on-investment. For clinical investigators and trialists, monitoring appeared to be little more than an on-site nuisance that overlooked or impeded activities that made a much more meaningful contribution to trial quality (e.g. randomization).
CTTI sponsored a series of workshops between 2009 and 2013 to understand the core purpose of monitoring and to evaluate more effective, efficient monitoring approaches. Workshop participants aligned on a new vision of monitoring as a proactive risk management tool facilitated by (1) understanding the key questions posed by a trial, (2) identifying the data and activities critical to addressing them and to protecting participants, and (3) selecting appropriate approaches (statistical, central, and/or on-site) to focus on these critical data and processes.
6,7 CTTI's monitoring project undercut the myth of 100% source data verification, a belief that had been constraining monitoring for decades. The concept of tailoring monitoring to a trial's design and stepping away from a one-size-fits-all, box-checking approach to quality excited stakeholders across the clinical trial ecosystem. This enthusiasm grew in 2011 when FDA issued draft guidance outlining a proactive, riskbased approach to monitoring, citing CTTI's work. 8 FDA's monitoring guidance, finalized in 2013, 9 signaled interest in defining a proactive quality paradigm broader than the quality control afforded by monitoring. The guidance stated that ''Monitoring, or oversight, alone cannot ensure quality. Rather, quality is an overarching objective that must be built into the clinical trial enterprise.'' CTTI once again served as the linchpin in developing a strategy and proposing a model for proactively integrating quality into clinical trials. CTTI's Quality by Design project, completed in 2016, 10 translated practices long-established in other industries, primarily manufacturing, into a dynamic and flexible quality planning approach for clinical development. The Quality by Design project outlined an approach to building quality into trial design, starting with prospective identification of trial data and processes critical to the credibility of the trial and to protection of participants. Understanding what is ''critical to quality'' for a trial permits tailoring of protocol design to eliminate unnecessary complexity and to avoid predictable errors in conduct; this understanding also allows oversight, including monitoring and auditing, to be similarly streamlined and focused (Figure 2) .
A key deliverable to facilitate this proactive quality approach was a document outlining a set of principles that forged a clear link between trial designers and quality professionals. 11 The principles are intended to stimulate proactive, cross-stakeholder dialogue and decision making about quality throughout trial design and planning. Moreover, they can be systematically and flexibly applied across the clinical trial enterprise to streamline trial design, prevent errors important to the generation of reliable evidence, and mitigate risks that may undermine trial conduct. Unlike previous attempts at quality improvement, these principles recognize the important role of scientific elements in trial design and quality, such as randomization, the choice of control, and statistical methods. Those seeking to apply quality by design principles can leverage CTTI's online toolkit 12 with resources to explore, teach, and deploy the approach across an organization.
CTTI's Quality by Design project is supporting the continued evolution of regulatory guidance on clinical trial quality. While ICH incorporated concepts from CTTI's monitoring work in an updated GCP guideline, 13 a 2017 ICH Reflection Paper outlined a plan for renovating additional guidelines relevant to clinical trial quality, starting with ICH E8, General Considerations for Clinical Trials.
14 Per the proposal, an updated E8 ''could identify a basic set of critical-to-quality factors generally relevant to the integrity and reliability of study conclusions and patient safety that sponsors should consider.'' This statement echoes language from CTTI's Quality by Design principles, which the reflection paper references. With ICH moving forward with its plan for renovation, CTTI could play a key role in the translation of the Quality by Design principles and project recommendations into the most effective and efficient global guidance. CTTI's advisory role in the development of these guidelines is crucial. While the phrase ''proactive quality'' is in vogue, there remains a risk of reverting to old habits. In many organizations, integrating quality-by-design requires sustained change management and an organization's will to learn from failures. Organizations must guard against simply translating existing checkboxes into ''key risk indicators'' or ''critical to quality elements,'' a practice that may lend the appearance of adopting quality-by-design while in actuality, the organization is avoiding the perceived challenges of change. Additionally, with staff in highly specialized roles, many clinical development organizations have become siloed over time. An unintended consequence is that the organization's broader vision of clinical trial design and methodology has been blurred. Compounding these issues is another risk: the difficulty of demonstrating how a short-term investment in building a proactive approach has the long-term value of prevention. These issues and their remediation consume attention and resources; risks that do not materialize due to proactive quality are harder to quantify. CTTI's Quality by Design toolkit is one resource that can support organizations in addressing these challenges, and the toolkit can be augmented over time as new challenges emerge.
Finally, CTTI's regulatory members can contribute significantly to sustaining a culture of proactive quality. This culture takes time to build in an organization, but can be destroyed overnight by perceived discrepancies between the risk-based approach to quality advocated in guidance and what is highlighted during inspections or communicated in enforcement actions. Modernized regulations and guidance must continue to be developed, adopted, and evolved in response to changes in the science of quality; inspectional approaches must keep pace with these changes and focus on critical quality aspects of trial conduct and reporting. As our understanding of clinical trial quality continues to evolve, the industry, as well as the patients and consumers it serves, will benefit from CTTI's continued engagement in promoting true quality and efficiency in the approval of new treatments and interventions.
